Myriam Delaunay
Overview
Explore the profile of Myriam Delaunay including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
533
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Toffart A, Meert A, Wallet F, Gibelin A, Guisset O, Gonzalez F, et al.
Ann Intensive Care
. 2023 Apr;
13(1):29.
PMID: 37072645
Background: Immune checkpoint inhibitors (ICI) have revolutionized the management of cancer. They can induce immune-related adverse events (irAE) leading to intensive care unit (ICU) admission. We aimed to describe irAEs...
2.
Gobbini E, Toffart A, Perol M, Assie J, Duruisseaux M, Coupez D, et al.
Clin Lung Cancer
. 2020 Jul;
21(5):e497-e510.
PMID: 32605892
Background: Immune checkpoint inhibitor (ICPi) rechallenge could represent an attractive option in non-small-cell lung cancer (NSCLC), yet no sufficient data supporting this strategy are available. This retrospective observational multicenter national...
3.
Delaunay M, Prevot G, Collot S, Guilleminault L, Didier A, Mazieres J
Eur Respir Rev
. 2019 Nov;
28(154).
PMID: 31694838
Immunotherapy has become a standard of care in oncology, following the recent approvals of cytotoxic T-lymphocyte-associated protein-4 and programmed cell death-1 inhibitors in lung cancer, melanoma, renal cell carcinoma, Hodgkin's...
4.
Guibert N, Jones G, Beeler J, Plagnol V, Morris C, Mourlanette J, et al.
Lung Cancer
. 2019 Sep;
137:1-6.
PMID: 31518912
Objectives: Tumor mutational burden is an emerging biomarker of response to immune checkpoint inhibitors (ICI), whose clinical adoption is challenging. We hypothesized that targeting limited but relevant genetic alterations in...
5.
Keller L, Guibert N, Casanova A, Brayer S, Farella M, Delaunay M, et al.
Acta Derm Venereol
. 2018 Nov;
99(2):206-210.
PMID: 30393817
Antibodies targeting immune checkpoints were recently approved for metastatic melanoma. However, not all patients will respond to the treatment and some will experience grade III-IV immune-related adverse events. Therefore, early...
6.
Guibert N, Delaunay M, Lusque A, Boubekeur N, Rouquette I, Clermont E, et al.
Lung Cancer
. 2018 May;
120:108-112.
PMID: 29748004
Background: Inhibitors of the PD-1/PD-L1 immune checkpoint have become a standard of care in non-small cell lung cancer (NSCLC). Patient selection, currently based on PD-L1 expression on tumor tissue, is...
7.
Delaunay M, Cadranel J, Lusque A, Meyer N, Gounant V, Moro-Sibilot D, et al.
Eur Respir J
. 2017 Aug;
50(2).
PMID: 28798088
Immunotherapy is becoming a standard of care for many cancers. Immune-checkpoint inhibitors (ICI) can generate immune-related adverse events. Interstitial lung disease (ILD) has been identified as a rare but potentially...
8.
Guibert N, Mazieres J, Delaunay M, Casanova A, Farella M, Keller L, et al.
Oncotarget
. 2017 Apr;
8(23):38056-38060.
PMID: 28445137
Objectives: Pseudo-progression is a rare but worrying situation for both clinicians and patients during immunotherapy. Dedicated ir-RECIST criteria have been established to improve this situation. However, this can be sometimes...
9.
Guibert N, Delaunay M, Mazieres J
Ther Adv Respir Dis
. 2015 Apr;
9(3):105-20.
PMID: 25827132
The use of immunotherapy that harnesses and enhances the innate powers of the immune system to fight cancer cells represents the most promising new cancer treatment approach since the development...